666816-91-7

Basic information

• Product Name: Linagliptin Impurity D
• Synonyms: Linagliptin Impurity D;tert-butyl (R)-(1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate;Linagliptin Impurity 21
• CAS NO: 666816-91-7
• Molecular Formula: C₂₀H₂₈N₆O₄
• Molecular Weight: 416.47412
• Mol File: 666816-91-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.32±0.1 g/cm3(Predicted)
• PKA: 9.38±0.70(Predicted)
• CAS DataBase Reference: Linagliptin Impurity D(CAS DataBase Reference)
• NIST Chemistry Reference: Linagliptin Impurity D(666816-91-7)
• EPA Substance Registry System: Linagliptin Impurity D(666816-91-7)

Safety Data

• Hazardous Substances Data: 666816-91-7(Hazardous Substances Data)

Usage

Description

Linagliptin Impurity D, also known as 3-Methyl-7-(2-butyn-1-yl)-8-[(R)-3-(tertbutyloxycarbonylamino)piperidin-1-yl]-xanthine, is a synthetic compound derived from the pharmaceutical industry. It is characterized by its unique chemical structure and properties, making it a valuable impurity in the synthesis of Linagliptin, a widely used antidiabetic drug.

Uses

Used in Pharmaceutical Industry:
Linagliptin Impurity D is used as a synthetic compound for the development and production of Linagliptin, an antidiabetic drug. It plays a crucial role in the synthesis process, contributing to the overall efficacy and safety of the final product.
Additionally, Linagliptin Impurity D may be utilized in research and development for the discovery of new pharmaceutical compounds with potential therapeutic applications. Its unique chemical structure and properties make it a valuable tool for exploring novel drug candidates and advancing the field of medicinal chemistry.

Upstream product

• 93703-24-3 3-methyl-8-bromoxanthine 
• 309956-78-3 (R)-piperidin-3-ylcarbamic acid tert-butyl ester 
• 666816-98-4 8-bromo-7-(but2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6–dione 

Downstream Products

• 668270-12-0 Linagliptin 

Relevant articles and documents

A preparation method of advantage geleg sandbank

The invention discloses a preparation method for Trajenta. The Trajenta is a high-purity Trajenta which is prepared by taking a raw material 8-bromo-7-(2-butynyl)-3-methylxanthine, namely a compound a as basic material, selecting appreciate reaction material ratio, reaction time and reaction conditions in substitution, deprotection and other reaction steps. The preparation method has the beneficial effects that a novel method for preparing the Trajenta is provided, and dimer impurities generated in the reaction process are effectively avoided, so that the high-purity Trajenta is obtained, the raw material of the reaction are easily available, the production cost is low, and industrial production requirement of the Trajenta can be met to the greatest extent.

METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN

The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.

8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein R is defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).